跳到正文
原文
NEJM· @NEJM · X·· 27 天前精选AI 评分65
AI 导读

NEJM 报道,在两项纳入活动性干燥综合征患者的试验中,每月一次 ianalumab 治疗 48 周时疾病活动度降幅大于安慰剂,但应答率和症状评分的差异不显著。这两项试验为 III 期 NEPTUNUS-1 和 NEPTUNUS-2,完整结果已发布,同期配发评论《Ianalumab in Sjögren's Disease — A First Step》。

推荐理由

两项 III 期试验显示 ianalumab 在 48 周降低干燥综合征疾病活动度优于安慰剂,但应答率与症状评分差异不显著。

正文

In two trials involving patients with active Sjögren’s disease, decreases in disease activity at 48 weeks were greater with monthly ianalumab than with placebo, but differences in response rates and symptom scores were not significant. Full results of the phase 3 NEPTUNUS-1 and NEPTUNUS-2 trials: https://nej.md/3VU4TAp

Editorial: Ianalumab in Sjögren’s Disease — A First Step https://nej.md/4ivvs7E

来源:NEJM · x.com